Clinical Trial Update: Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma [Phase 2]

View source ↗

Summary

Completed Phase 2 study of sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Clear Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Clear Cell Carcinoma | Phase 2 | Status: COMPLETED